Sampra Pharma Private Limited
About Sampra Pharma Private Limited
Data last updated:
Sampra Pharma Private Limited is a private limited company based in Lucknow, Uttar Pradesh, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 17 January 2014 and has been in existence for over 12 years.
The company is registered with the Registrar of Companies (ROC), Kanpur, under CIN U24100UP2014PTC062039. The company has 1 GST registration on record, which is no longer active.
The company has an authorised share capital of ₹2 Lakh and a paid-up capital of ₹10 Lakh. It is led by directors Shailesh Prabhunath Gupta and Sunil Singh.
Its last annual general meeting (AGM) was held on 21 September 2022, and its latest financial statements are for the year ended 31 March 2022. The registered office is at Es – 1/216 217 Sector – A Sry Paltan Chhavni Aliganj, Lucknow, Uttar Pradesh, India – 226021.
As per the financials filed for FY 2019, the company reported a revenue of ₹12.35 Lakh, a decline of 57% compared to the previous year. For the same year it recorded a net loss of ₹36,712 (net margin -3%) and EBITDA of -₹36,712 (EBITDA margin -3%). Revenue has grown at a compounded annual rate (CAGR) of 22% over three years.
As per MCA filings, the company has open charges of ₹8 Lakh on record.
The current compliance status is marked as compliant by the Registrar of Companies.
- EmailLocked
- TelephoneLocked
- WebsiteLocked
- Social MediaLocked
- Registered AddressEs – 1/216 217 Sector – A Sry Paltan Chhavni Aliganj, Lucknow, Uttar Pradesh, India – 226021
- IndustryPharma, Drug Formulation & Development
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
- One PDF report, delivered after checkout
Financials of Sampra Pharma Private Limited FY 2022 filings available
Sampra Pharma Private Limited reported revenue of ₹12.35 Lakh (down 57% YoY) for FY 2019.
Compounded Annual Growth Rate (CAGR) of Sampra Pharma Private Limited
Revenue fell 57% in the latest year, but over three years it has grown at a compounded annual rate (CAGR) of 22%. EBITDA fell 505% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary of Sampra Pharma Private Limited
| Metrics | FY 2018-19 | FY 2017-18 | FY 2016-17 | FY 2015-16 | FY 2014-15 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | ₹12.35 Lakh | •••• | •••• | •••• | •••• |
| Other Income | •••• | •••• | •••• | •••• | •••• |
| Total Revenue | •••• | •••• | •••• | •••• | •••• |
| Cost of Materials Consumed | •••• | •••• | •••• | •••• | •••• |
| Employee Benefit Expense | •••• | •••• | •••• | •••• | •••• |
| Finance Costs | •••• | •••• | •••• | •••• | •••• |
| Depreciation and Amortisation | •••• | •••• | •••• | •••• | •••• |
| Other Expenses | •••• | •••• | •••• | •••• | •••• |
| Total Expenses | •••• | •••• | •••• | •••• | •••• |
| EBITDA | -₹36,712 | •••• | •••• | •••• | •••• |
| Profit Before Tax | •••• | •••• | •••• | •••• | •••• |
| Tax Expense | •••• | •••• | •••• | •••• | •••• |
| Net Profit (PAT) | -₹36,712 | •••• | •••• | •••• | •••• |
| Balance Sheet | |||||
| Share Capital | •••• | •••• | •••• | •••• | •••• |
| Reserves and Surplus | •••• | •••• | •••• | •••• | •••• |
| Net Worth (Total Equity) | •••• | •••• | •••• | •••• | •••• |
| Long-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Short-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Trade Payables | •••• | •••• | •••• | •••• | •••• |
| Total Liabilities | •••• | •••• | •••• | •••• | •••• |
| Fixed Assets | •••• | •••• | •••• | •••• | •••• |
| Investments | •••• | •••• | •••• | •••• | •••• |
| Inventories | •••• | •••• | •••• | •••• | •••• |
| Trade Receivables | •••• | •••• | •••• | •••• | •••• |
| Cash and Bank Balance | •••• | •••• | •••• | •••• | •••• |
| Total Assets | •••• | •••• | •••• | •••• | •••• |
Financial Ratios of Sampra Pharma Private Limited
| Metrics | FY 2018-19 | FY 2017-18 | FY 2016-17 | FY 2015-16 | FY 2014-15 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | -3% | •••• | •••• | •••• | •••• |
| Net Profit Margin | -3% | •••• | •••• | •••• | •••• |
| Return on Equity (ROE) | •••• | •••• | •••• | •••• | •••• |
| Return on Capital Employed (ROCE) | •••• | •••• | •••• | •••• | •••• |
| Return on Assets (ROA) | •••• | •••• | •••• | •••• | •••• |
| Liquidity and Debt | |||||
| Current Ratio | •••• | •••• | •••• | •••• | •••• |
| Quick Ratio | •••• | •••• | •••• | •••• | •••• |
| Debt-to-Equity Ratio | •••• | •••• | •••• | •••• | •••• |
| Interest Coverage Ratio | •••• | •••• | •••• | •••• | •••• |
| Efficiency and Growth | |||||
| Asset Turnover | •••• | •••• | •••• | •••• | •••• |
| Receivable Days | •••• | •••• | •••• | •••• | •••• |
| Payable Days | •••• | •••• | •••• | •••• | •••• |
| Inventory Days | •••• | •••• | •••• | •••• | •••• |
| Revenue Growth | •••• | •••• | •••• | •••• | •••• |
| Net Profit Growth | •••• | •••• | •••• | •••• | •••• |
Paid data: the figures shown as dots are available after purchase of the company report. Figures as filed with the MCA in Form AOC-4. The full year-wise statements and ratios of Sampra Pharma are in the company report.
Financial statements from 2015
Earlier years and trend charts are in the company report.
- Income statements
- Balance sheets
- Cash-flow statements
- Ratios and benchmarks
Verified entity values are shown only after access is granted.
Peer Comparison of Sampra Pharma Private Limited
Sampra Pharma Private Limited is compared with the companies closest to it by revenue in the Pharma industry (Formulations). Net profit, margin and employee counts of each company are in the company report.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Dolce Pharmaceuticals Private Limited | ₹12.5 Lakh (FY 2019) | •••• | •••• | 145285.0% | •••• | Boisar, Maharashtra, India |
| Rajyoti Remedies Private Limited | ₹12.5 Lakh (FY 2024) | •••• | •••• | -17.0% | •••• | Bihar, India |
| Rashika Medicare Private Limited | ₹12.39 Lakh (FY 2025) | •••• | •••• | 106.0% | •••• | Gurgaon, Haryana, India |
| Craton Pharmaceuticals Private Limited | ₹12.37 Lakh (FY 2021) | •••• | •••• | -29.0% | •••• | Vadodara, Gujarat, India |
| Gambiabiotech India Private Limited | ₹12.37 Lakh (FY 2025) | •••• | •••• | -40.0% | •••• | Bhopal, Madhya Pradesh, India |
| Sampra Pharma Private Limited this company | ₹12.35 Lakh (FY 2019) | •••• | •••• | -57.0% | •••• | Lucknow, Uttar Pradesh, India |
| Fantina Pharma Private Limited | ₹12.33 Lakh (FY 2023) | •••• | •••• | -29.0% | •••• | Sitamarhi, Bihar, India |
| Anee Smith Private Limited | ₹12.33 Lakh (FY 2025) | •••• | •••• | 290.0% | •••• | Mohali, Punjab, India |
| Sofgel Capsulation Private Limited | ₹12.29 Lakh (FY 2025) | •••• | •••• | -75.0% | •••• | Kanpur, Uttar Pradesh, India |
| Avila Pharmaceuticals Private Limited | ₹12.26 Lakh (FY 2021) | •••• | •••• | •••• | Thane, Maharashtra, India | |
| Corsants Life Sciences Private Limited | ₹12.24 Lakh (FY 2025) | •••• | •••• | -23.0% | •••• | New Delhi, Delhi, India |
Peers are the five companies nearest above and the five nearest below Sampra Pharma by revenue in the Pharma industry (Formulations), from the latest filed financials of each company. Net profit, margin and employee counts of each peer are in the company report.
Auditor Details of Sampra Pharma Private Limited
Sampra Pharma Private Limited is audited by DIWAKAR & COMPANY for the financial year 2019.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| DIWAKAR & COMPANY | Locked | Locked | Locked |
Complete auditor history
Appointment and cessation dates and past auditor changes are in the company report.
- Appointment status
- Appointment dates
- Cessation dates
- Auditor changes
Verified entity values are shown only after access is granted.
Board of Directors of Sampra Pharma Private Limited
Sampra Pharma has 2 current directors and 3 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Shailesh Prabhunath Gupta Also directs: Lumina Solar Private Limited, Pay100 Marketing Private Limited | Director | 16 Jul 2022 | 4 Years 2 Months | Current |
| Sunil Singh | Director | 18 Jan 2024 | 2 Years 8 Months | Current |
Ownership and Shareholding of Sampra Pharma Private Limited
Shareholding and ownership data
Promoter, institutional, public and beneficial ownership figures are in the company report.
- Ownership categories
- Historical changes
- Group structure
- FII and DII holdings
Verified entity values are shown only after access is granted.
Charges & Borrowings of Sampra Pharma Private Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 17 Aug 2018 | United Bank of India | ₹8 Lakh | Open |
Total charge records: 1 View all charges
Employees and EPFO Compliance at Sampra Pharma Private Limited
Employment history and EPFO contributions of people linked to Sampra Pharma.
Employee and EPFO history
Monthly headcount, contribution history and filing status are in the company report.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
Recent Activity on Sampra Pharma Private Limited
Sampra Pharma Private Limited has 5 board changes on record since 2022: 2 appointments and 3 cessations. The latest: Barun Kumar Singh ceased to be Director on 18 Jan 2024.
Credit Ratings, Litigation & Regulatory Alerts for Sampra Pharma Private Limited
Credit ratings, litigation, and regulatory alerts
Credit ratings, court records and regulatory alerts are in the company report.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
MSME Payment Delays by Sampra Pharma Private Limited
MSME payment history
Amounts due to small suppliers, the reasons given and MSME-1 filings are in the company report.
- Outstanding amounts
- Delay periods and reasons
- MSME-1 filing history
- Vendor payment signals
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of Sampra Pharma Private Limited
Corporate group structure
Parent, subsidiary, associate and joint venture records with holdings are in the company report.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
GST Compliance of Sampra Pharma Private Limited
Sampra Pharma has 1 GST registration on record, and it has been cancelled or is inactive. Only active GST numbers are listed on this page.
GST registrations and filing compliance
State-wise GST registrations, return filing status and HSN or SAC codes are in the company report.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
MCA Filings & Documents of Sampra Pharma Private Limited
MCA filings and documents
Filed forms, annual returns, financial statements and charge filings with their dates are in the company report.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Sampra Pharma Private Limited
Sampra Pharma is an active private limited company based in Lucknow, Uttar Pradesh, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 17 January 2014 (12+ years old) and is registered under CIN U24100UP2014PTC062039.
Sampra Pharma reported revenue of ₹12.35 Lakh for FY 2019 (down 57% YoY).
Sampra Pharma has 2 current directors:
- Shailesh Prabhunath Gupta - Director
- Sunil Singh - Director
Sampra Pharma reported a net loss of ₹36,712 (net margin -3%) and EBITDA of -₹36,712 (EBITDA margin -3%) for FY 2019, as per its filed financial statements.
The compounded annual growth rate (CAGR) of the revenue of Sampra Pharma is 22% over three years. In the latest year (FY 2019) revenue fell 57%. CAGR is the steady yearly rate that links the first and the last year.
No. Sampra Pharma has 1 GST registration on record and it is cancelled or inactive.
The CIN (Corporate Identification Number) of Sampra Pharma is U24100UP2014PTC062039. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Sampra Pharma was incorporated on 17 January 2014, making it 12+ years old. It is registered with the Registrar of Companies, Kanpur.
The peers of Sampra Pharma by revenue are Dolce Pharmaceuticals Private Limited, Rajyoti Remedies Private Limited, Rashika Medicare Private Limited, Craton Pharmaceuticals Private Limited, Gambiabiotech India Private Limited and 5 more, all in the Pharma industry (Formulations).
Barun Kumar Singh ceased to be Director on 18 Jan 2024. Sunil Singh was appointed as Director on 18 Jan 2024. Indrajeet Singh ceased to be Director on 16 Jul 2022. Sampra Pharma has 5 board changes on record in total.
The registered office of Sampra Pharma is at Es – 1216 217 Sector – A Sry Paltan Chhavni Aliganj, Lucknow, Uttar Pradesh, India – 226021.